Pharma BD Deal Intelligence

Otsuka Pharmaceutical Co., Ltd. / Avanir Pharmaceuticals, Inc.

2014 · Acquisition/Merger · $3.5B · Complete

Announcement Sentiment

Positive

Otsuka agreed to acquire Avanir Pharmaceuticals for $17.00 per share, valuing the company at approximately $3.5B. Deal added Nuedexta for pseudobulbar affect and the late-stage AVP-786 program for Alzheimer's agitation, completing Otsuka's transformation toward a global CNS pharma. Closed Q1 2015.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Assets Terminated

Assessment window: 5yr post-close.

Key facts

Announced Dec 02, 2014
Closed Mar 09, 2015
Deal value $3.5B
Deal type Acquisition/Merger
Therapeutic area Pseudobulbar affect, Alzheimer's agitation, neurologic disease
Indications Pseudobulbar affect, Alzheimer's agitation, neurologic disease
Key assets Nuedexta (dextromethorphan/quinidine) and AVP-786
Mechanism NMDA antagonist + sigma-1 agonist combination (dextromethorphan/quinidine)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals